US 11,952,407 B2Granted

Pharmaceutical preparation

AssigneeFerring International Center S.A.

InventorsIan Cottingham, Daniel Plaksin, Richard Boyd White

Life of this patent

Estimating the term…

Abstract

Preparations including recombinant FSH (rFSH).

Claims5

Dependent claims

Recombinant follicle stimulating hormone (FSH) comprising α2,3- and α2,6-sialylation, produced or expressed in a human cell line, wherein from 5% to 20% of the total sialylation of the recombinant FSH is α2,6-sialylation.

Dependencies are inferred from the claim text.

Facts

Application: 17/246,348Filed 30 Apr 2021 · continuation
Priority: EP 0825152825 Apr 2008
Published: US 2021/0332099 A128 Oct 2021
Granted: 9 Apr 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 14/59
Hormones: follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH];…
A61P 5/06
Drugs for disorders of the endocrine system: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
A61P 5/10
Drugs for disorders of the endocrine system: of the posterior pituitary hormones, e.g. oxytocin, ADH
A61P 15/00
Drugs for genital or sexual disorders

Family

Application61/045,424Us provisional application · filed 16 Apr 2008
PCT/GB2009/000978Parent of this continuation · filed 16 Apr 2009
Application14/541,852Parent of this continuation · filed 14 Nov 2014
Application15/238,362Parent of this continuation · filed 16 Aug 2016
Application15/690,061Parent of this continuation · filed 29 Aug 2017
US 2021/0332099 A1Pre-grant publication · published 28 Oct 2021
US 10,995,128 B2Parent of this continuation
US 9,771,407 B2Parent of this continuation
US 9,546,204 B2Parent of this continuation
Application12/988,218Parent of this continuation
US 8,951,967 B2Parent of this continuation
US 2011/0105398 A1Published application
US 2015/0065695 A1Published application
US 2016/0347811 A1Published application
US 2018/0079794 A1Published application
US 11,952,407 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Facts

Application

17/246,348Filed 30 Apr 2021 · continuation

Priority

EP 0825152825 Apr 2008

Published

US 2021/0332099 A128 Oct 2021

Granted

9 Apr 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 14/59
Hormones: follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH];…
A61P 5/06
Drugs for disorders of the endocrine system: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
A61P 5/10
Drugs for disorders of the endocrine system: of the posterior pituitary hormones, e.g. oxytocin, ADH
A61P 15/00
Drugs for genital or sexual disorders

Family

Application61/045,424Us provisional application · filed 16 Apr 2008

PCT/GB2009/000978Parent of this continuation · filed 16 Apr 2009

Application14/541,852Parent of this continuation · filed 14 Nov 2014

Application15/238,362Parent of this continuation · filed 16 Aug 2016

Application15/690,061Parent of this continuation · filed 29 Aug 2017

US 2021/0332099 A1Pre-grant publication · published 28 Oct 2021

US 10,995,128 B2Parent of this continuation

US 9,771,407 B2Parent of this continuation

US 9,546,204 B2Parent of this continuation

Application12/988,218Parent of this continuation

US 8,951,967 B2Parent of this continuation

US 2011/0105398 A1Published application

US 2015/0065695 A1Published application

US 2016/0347811 A1Published application

US 2018/0079794 A1Published application

US 11,952,407 B2This patent

From the US filing history. Foreign family members aren’t listed.